ANNX — Annexin Pharmaceuticals AB (publ) Cashflow Statement
0.000.00%
Last trade - 00:00- SEK196.57m
- SEK180.23m
Annual cashflow statement for Annexin Pharmaceuticals AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.7 | -51.2 | -40.7 | -44.2 | -50.5 |
| Non-Cash Items | 4.47 | 4.47 | 0.193 | 0.193 | 0.193 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.066 | 1.74 | -0.634 | 0.58 | 0.058 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -39.2 | -45 | -41.2 | -43.4 | -50.2 |
| Capital Expenditures | — | 0 | 0 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.096 | 0 | -0.26 | 0.096 | 0 |
| Change in Net Investments | |||||
| Cash from Investing Activities | -0.096 | 0 | -0.26 | 0.096 | 0 |
| Financing Cash Flow Items | -7.62 | -10.3 | -0.047 | -2.9 | 0.095 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 53.2 | 76.4 | 23.1 | 33.6 | 45.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.9 | 31.3 | -18.4 | -9.7 | -5.08 |